

Mediclinic International plc  
(Incorporated in England and Wales)  
Company Number: 08338604  
LSE Share Code: MDC  
JSE Share Code: MEI  
NSX Share Code: MEP  
ISIN: GB00B8HX8Z88  
LEI: 2138002S5BSBIZTD5I60  
("Mediclinic", the "Company", or the "Group")

6 April 2023

TR-1: Standard form for notification of major holdings

**1. Issuer Details**

**ISIN**

GB00B8HX8Z88

**Issuer Name**

MEDICLINIC INTERNATIONAL PLC

**UK or Non-UK Issuer**

UK

**2. Reason for Notification**

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

**3. Details of person subject to the notification obligation**

**Name**

The Goldman Sachs Group, Inc.

**City of registered office (if applicable)**

Wilmington, Delaware

**Country of registered office (if applicable)**

USA

**4. Details of the shareholder**

**Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above**

**City of registered office (if applicable)**

**Country of registered office (if applicable)**

**5. Date on which the threshold was crossed or reached**

03-Apr-2023

**6. Date on which Issuer notified**

05-Apr-2023

## 7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	0.010572	1.221842	1.232414	9085901
Position of previous notification (if applicable)	1.074447	3.974818	5.049265	

## 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

### 8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00B8HX8Z88		77943		0.010572
Sub Total 8.A	77943		0.010572%	

### 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Securities Lending	Open		9007921	1.221837
Sub Total 8.B1			9007921	1.221837%

### 8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Swap	30-May-2023		Cash	37	0.000005
Sub Total 8.B2				37	0.000005%

## 9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Goldman Sachs Group, Inc. (Chain 1)				
The Goldman Sachs Group, Inc. (Chain 1)	Goldman Sachs (UK) L.L.C.			
The Goldman Sachs Group, Inc. (Chain 1)	Goldman Sachs Group UK Limited			
The Goldman Sachs Group, Inc. (Chain 1)	Goldman Sachs International			
The Goldman Sachs Group, Inc. (Chain 2)				
The Goldman Sachs Group, Inc. (Chain 2)	GSAM Holdings LLC			
The Goldman Sachs Group, Inc. (Chain 2)	Goldman Sachs Asset Management, L.P.			
The Goldman Sachs Group, Inc. (Chain 3)				
The Goldman Sachs Group, Inc. (Chain 3)	Goldman Sachs Bank USA			
The Goldman Sachs Group, Inc. (Chain 3)	Goldman Sachs Bank Europe SE			
The Goldman Sachs Group, Inc. (Chain 4)				
The Goldman Sachs Group, Inc. (Chain 4)	Goldman Sachs & Co. LLC			

#### 10. In case of proxy voting

**Name of the proxy holder**

**The number and % of voting rights held**

**The date until which the voting rights will be held**

## 11. Additional Information

Please note, positions previously reportable are now exempt under the market making exemption as they are below the 10% limit.

Please note, the total amount of voting rights has been rounded to 6 decimal places therefore there is a possibility of a rounding error.

General email contact:

[gs-regops-emea-position-enquiries@gs.com](mailto:gs-regops-emea-position-enquiries@gs.com)

## 12. Date of Completion

05-Apr-2023

## 13. Place Of Completion

Warsaw

## ABOUT MEDICLINIC INTERNATIONAL PLC

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 December 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and five day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 750 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("**LSE**") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

## **CONTACT INFORMATION**

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

+44 (0)20 3786 8181

ir@mediclinic.com

Media queries

FTI Consulting

Ben Atwell/Ciara Martin – UK

+44 (0)20 3727 1000

Sherryn Schooling – South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: [www.mediclinic.com](http://www.mediclinic.com)

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd